Smart Eye
GÖTEBORG, SE / ACCESSWIRE / January 4, 2022 / Smart Eye (STO:SEYE) (OTC PINK:SMTEF) (FRA:SE9)
The company's groundbreaking Automotive Interior Sensing solution combines driver monitoring and cabin monitoring to improve road safety and mobility experiences.
Smart Eye, the global leader in Human Insight AI, today announced that it has been named a CES® 2022 Innovation Awards Honoree for Smart Eye Automotive Interior Sensing. The recognition comes ahead of CES 2022, happening Jan. 5-7 in Las Vegas, NV and digitally.
Smart Eye Automotive Interior Sensing combines the company's industry-leading driver monitoring system (DMS) with cabin monitoring to provide deep, human-centric insight into what is happening inside a vehicle. The system understands the state of the driver, the cabin and the backseat passengers, by detecting eye gaze, head movement, body posture, occupancy, activities, children, pets and objects. Powered by Affectiva's Emotion AI, it also captures nuanced emotions, reactions and facial expressions. In turn, Smart Eye enables OEMs and Tier 1s to build next generation vehicles that improve road safety by understanding dangerous driving behavior, and unlock features and services that enhance wellness, comfort and entertainment.
Smart Eye Automotive Interior Sensing is a multi-modal solution built with computer vision, machine learning and massive amounts of real-world automotive data. With a flexible camera position using the latest optical RGB and IR sensors, the system runs in real time on low-power embedded systems.
"We're so excited to receive this recognition of our work in Interior Sensing," said Martin Krantz, Founder and CEO of Smart Eye. "For years, Smart Eye has held a definitive leadership position in the driver monitoring system (DMS) market. Now, we are expanding our view beyond just the driver, to monitor the full cabin, to understand what is happening inside a vehicle. The industry is rapidly adopting these multi-modal Interior Sensing solutions, in response to evolving requirements for advanced safety features and next-generation mobility experiences. We're proud to be at the forefront of this movement."
The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. Those with the highest rating receive the "Best of Innovation" distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. This year's CES Innovation Awards program received a record-high number of submissions, with 1,800 companies entering.
Smart Eye will participate in Digital CES and will host remote, live technology demos of its latest and greatest automotive technology for select clients and partners during the week of CES and beyond.
Learn more about Smart Eye Automotive Interior Sensing in this overview video: https://youtu.be/jRdMaL0nkSI
Learn more about Smart Eye's activities during CES 2022: smarteye.se/ces-2022
The CES 2022 Innovation Awards honorees, including product descriptions and photos, can be found at CES.tech/innovation.
About Smart Eye
Smart Eye is the global leader in Human Insight AI, technology that understands, supports and predicts human behavior in complex environments. Together with its subsidiaries Affectiva and iMotions, the company is bridging the gap between humans and machines for a safe and sustainable future.
Smart Eye offers road-ready Driver Monitoring Systems and next-level Interior Sensing solutions built on two decades of automotive experience. Smart Eye's technology is embedded in next-generation vehicles as OEM or Tier 1 solutions and has been selected by 13 of the world's leading car manufacturers for 89 car models. Smart Eye also provides complete hardware and software solutions for fleet and aftermarket, powering vehicles on the road today.
As the preferred partner to the automotive industry, Smart Eye is leading the way towards safer, more sustainable transportation and mobility experiences enhancing wellness, comfort, and entertainment.
Smart Eye was founded in 1999, is publicly traded and headquartered in Sweden with offices in the US, UK, Germany, Denmark, Egypt, Japan, Singapore, and China. Learn more at: www.smarteye.ai.
Press Contact:
Hailey Melamut
hailey.melamut@walkersands.com
Attachments
Smart Eye Automotive Interior Sensing Named CES 2022 Innovation Awards Honoree
SOURCE: Smart Eye
View source version on accesswire.com:
https://www.accesswire.com/680878/Smart-Eye-Automotive-Interior-Sensing-Named-CES-2022-Innovation-Awards-Honoree
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom